Elucidating the Role and Therapeutic Vulnerability of Sema5B in RCC
Abstract
The kidney removes wastes from our body and maintains a healthy balance of water, salts, and minerals. When we are exposed to toxins, our two kidneys help to eliminate them from our bodies as well. Hence, the toxins one point in time, travel through the kidneys that increasing the chance of kidney cancer. Exposure to toxic chemicals while on a military base or during deployment can lead to kidney cancer among a great deal of Veterans, and not only Veterans but anyone can be diagnosed with kidney cancer in their lifetime for some known and unknown reasons. In the United States, kidney cancer is among the top 10 malignancies in both men and women. The American Cancer Society s most recent estimates for kidney cancer in the United States for 2022 note that about 79,000 new cases of kidney cancer (50,290 in men and 28,710 in women) will be diagnosed and about 13,920 people (8,960 men and 4,960 women) will die from this disease. Clear cell renal cell carcinoma histology (ccRCC) is the most frequent form of this cancer. Although outcomes are excellent for patients with tumors confined to the kidney, patients with the advanced disease face unfavorable outcomes despite several approved therapies. This underscores the need for newer therapies. Semaphorin 5B (Sema5B) protein is a factor that becomes abundant in RCC patient tumors compared to adjacent normal kidney tissues. Our group had already reported that Sema5B promotes renal cancer growth, but its mechanism is unclear. Moreover, Sema5B s role in RCC metastasis as well as its therapeutic vulnerabilities remain unexplored. Based on our solid preliminary data, I will deal with these possibilities during the Kidney Cancer Research Program Academy of Kidney Cancer Investigators Early Career Scholar Award. The short-term impact of this proposal is that we will likely establish a therapeutic vulnerability for renal cancers that have high Sema5B content. As a result, those patients with high Sema5B can have a customized regimen of therapies for a better outcome. The long-term impact of the proposal is huge, as Sema5B is high in most of the RCC tumors (greater than 50%) and, therefore, the proposal will impact the majority of RCC patients.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252310783
Entities
People
- Anirban Kundu
Organizations
- United States Army
- University of Alabama at Birmingham